Bristol Myers Colorectal Cancer Treatment Goes Under Priority FDA Review
benzinga.com/25/02/43919389/bristol-myers-opdivo-plus-yervoy-treatment-goes-under-priority-fda-review-for-colorectal-cancer
On Monday, the FDA accepted the supplemental biologics license application (sBLA) for Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a potential first-line treatment option for adult and pediatric patients (12 years and older) with unresectable or…
This story appeared on benzinga.com, 2025-02-24 17:24:57.